ATE354370T1 - Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen - Google Patents

Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen

Info

Publication number: ATE354370T1
Authority: AT; Austria
Prior art keywords: incapacitated; whole cell; bacterial; bacterium; lys minus
Prior art date: 2001-09-27

Application number

AT02763771T

Other languages

English (en)

Inventor

Janakiraman Ramachandran

Sriram Padmanabhan

Bharathi Sriram

Original Assignee

Gangagen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-27

Filing date

2002-09-27

Publication date

2007-03-15

2002-09-27 Application filed by Gangagen Inc filed Critical Gangagen Inc

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE354370T1 publication Critical patent/ATE354370T1/de

Links

230000001580 bacterial effect Effects 0.000 title abstract 5
230000002163 immunogen Effects 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
241000894006 Bacteria Species 0.000 abstract 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
230000028993 immune response Effects 0.000 abstract 2
230000010076 replication Effects 0.000 abstract 2
241001515965 unidentified phage Species 0.000 abstract 2
101710126949 Lysin Proteins 0.000 abstract 1
229960001212 bacterial vaccine Drugs 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
230000002950 deficient Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
230000003362 replicative effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT02763771T 2001-09-27 2002-09-27 Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen ATE354370T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32579601P	2001-09-27	2001-09-27

Publications (1)

Publication Number	Publication Date
ATE354370T1 true ATE354370T1 (de)	2007-03-15

Family

ID=23269486

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02763771T ATE354370T1 (de)	2001-09-27	2002-09-27	Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen

Country Status (9)

Country	Link
US (1)	US6913753B2 (de)
EP (1)	EP1438066B1 (de)
JP (2)	JP4554206B2 (de)
AT (1)	ATE354370T1 (de)
CA (1)	CA2461710C (de)
DE (1)	DE60218327T2 (de)
ES (1)	ES2282460T3 (de)
MX (1)	MXPA04002866A (de)
WO (1)	WO2003026690A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020192676A1 (en) *	2001-06-18	2002-12-19	Madonna Angelo J.	Method for determining if a type of bacteria is present in a mixture
MXPA04002899A (es) *	2001-09-27	2005-07-01	Gangen Inc	Bacteriofagos deficientes en lisina, que tienen inmunogenicidad reducida.
JP4490112B2 (ja) *	2002-04-12	2010-06-23	コロラド・スクール・オブ・マインズ	標的細菌性細胞を感染させるためにファージを使用する低濃度の標的細菌を検出するための方法
US20050129711A1 (en) *	2002-11-14	2005-06-16	Janakiraman Ramachandran	Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression
WO2008157384A2 (en) *	2007-06-15	2008-12-24	Microphage Incorporated	Method of detection of microorganisms with enhanced bacteriophage amplification
US20110097702A1 (en) *	2005-03-31	2011-04-28	Voorhees Kent J	Methods and compositions for in situ detection of microorganisms on a surface
WO2006105504A1 (en) *	2005-03-31	2006-10-05	Microphage Incorporated	Apparatus and method for detecting microorganisms using flagged bacteriophage
CA2672246A1 (en)	2006-06-30	2008-03-13	Rosetta Genomics Ltd	Detecting nucleic acids
US8697434B2 (en) *	2008-01-11	2014-04-15	Colorado School Of Mines	Detection of phage amplification by SERS nanoparticles
US9441204B2 (en) *	2008-04-03	2016-09-13	Colorado School Of Mines	Compositions and methods for detecting Yersinia pestis bacteria
CN103635584B (zh)	2011-04-12	2017-10-27	冈戈根股份有限公司	嵌合抗菌多肽
GB201600075D0 (en) *	2016-01-03	2016-02-17	Glaxosmithkline Biolog Sa	Immunogenci composition
US10973908B1 (en)	2020-05-14	2021-04-13	David Gordon Bermudes	Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en)	2020-07-22	2026-01-27	David Gordon Bermudes	Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2025208072A1 (en) *	2024-03-29	2025-10-02	The General Hospital Corporation	Methods and materials for treating disorders related to bacterial infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US6130082A (en)	1988-05-05	2000-10-10	American Cyanamid Company	Recombinant flagellin vaccines
GB9726233D0 (en) *	1997-12-11	1998-02-11	Medeva Europ Ltd	Vaccines containing attenuated bacteria
MXPA04002899A (es) *	2001-09-27	2005-07-01	Gangen Inc	Bacteriofagos deficientes en lisina, que tienen inmunogenicidad reducida.

2002
- 2002-09-27 ES ES02763771T patent/ES2282460T3/es not_active Expired - Lifetime
- 2002-09-27 EP EP02763771A patent/EP1438066B1/de not_active Expired - Lifetime
- 2002-09-27 DE DE60218327T patent/DE60218327T2/de not_active Expired - Lifetime
- 2002-09-27 US US10/259,164 patent/US6913753B2/en not_active Expired - Lifetime
- 2002-09-27 AT AT02763771T patent/ATE354370T1/de not_active IP Right Cessation
- 2002-09-27 CA CA2461710A patent/CA2461710C/en not_active Expired - Fee Related
- 2002-09-27 JP JP2003530325A patent/JP4554206B2/ja not_active Expired - Fee Related
- 2002-09-27 MX MXPA04002866A patent/MXPA04002866A/es active IP Right Grant
- 2002-09-27 WO PCT/US2002/030844 patent/WO2003026690A1/en not_active Ceased
2010
- 2010-04-01 JP JP2010084948A patent/JP2010180227A/ja active Pending

Also Published As

Publication number	Publication date
CA2461710C (en)	2013-01-15
US6913753B2 (en)	2005-07-05
CA2461710A1 (en)	2003-04-03
EP1438066B1 (de)	2007-02-21
WO2003026690A9 (en)	2004-09-16
MXPA04002866A (es)	2005-06-06
JP2010180227A (ja)	2010-08-19
JP4554206B2 (ja)	2010-09-29
DE60218327T2 (de)	2007-10-31
EP1438066A1 (de)	2004-07-21
JP2005508912A (ja)	2005-04-07
WO2003026690A1 (en)	2003-04-03
DE60218327D1 (de)	2007-04-05
EP1438066A4 (de)	2005-10-12
US20030152589A1 (en)	2003-08-14
ES2282460T3 (es)	2007-10-16

Legal Events

Date	Code	Title	Description
2007-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE354370T1 (de)	2007-03-15	Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen
NZ291262A (en)	1999-02-25	E. coli heat-labile enterotoxin derivatives and their use as oral adjuvants
BR0113822A (pt)	2003-06-24	Vacina
MXPA02005639A (es)	2004-09-10	Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
ATE489968T1 (de)	2010-12-15	Proteosom-liposaccharid-vakzine-adjuvans
DE69838383D1 (de)	2007-10-18	Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
NO20015073D0 (no)	2001-10-18	Vaksiner
HUP0000992A2 (hu)	2000-11-28	Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
WO2003082183A3 (en)	2004-01-15	Protein-based streptococcus pneumoniae vaccines
SE9003198L (sv)	1990-10-05	Fiskvaccin omfattande en virulent, invasiv bakterie
RU2008102654A (ru)	2009-07-27	Инактивированные химерные вакцины и связанные с ними способы применения
WO2005035558A3 (en)	2005-10-13	Piscirickettsia salmonis antigens and use thereof
ATE268384T1 (de)	2004-06-15	Analog von haemophilus hin47 mit verminderter protease aktivität
ATE458496T1 (de)	2010-03-15	Hiv-vakzine und anwendungsverfahren
WO2002034773A3 (en)	2003-03-13	Streptococcal genes
NO20013102D0 (no)	2001-06-21	Gener, proteiner og deres anvendelse
DK0573527T3 (da)	1999-06-07	Fremstilling og anvendelse af formalindræbte, kolonisationsfaktor-antigen(CFA)-udtrykkende E. coli-organismer til vaccinati
DE60143810D1 (de)	2011-02-17	Vakzine gegen ipnv die aus hefezellen isoliert werden
RU2004129738A (ru)	2005-07-10	Бактериальные споры
CY1107560T1 (el)	2013-03-13	Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
EE200200157A (et)	2003-04-15	Vaktsiin
TW200509964A (en)	2005-03-16	VP1 of foot-and-mouth disease virus
Tafuku et al.	2012	Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
CA1319634C (en)	1993-06-29	Vaccine
Rogers et al.	1972	Sensitization of guinea pigs to herpes simplex virus